Drugs / Hemin
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00882804 | Feb → Apr 2009 | — | Mayo Clinic | Completed | No outcome recorded |
| Phase 21 trial · 1 met primary | ||||||
| Phase 2 | NCT02922413 | Oct 2015 → Dec 2023 | acute intermittent porphyria, hereditary coproporphyria, variegate porphyria | The University of Texas Medical Branch, Galveston | Terminated | Met primary Stop: Enrollment |
| Comparator or background therapy2 trials | ||||||
| Phase 2 | NCT01855841 Comparator | Apr 2012 → Jun 2021 | acute pancreatitis | Erasme University Hospital | Completed | No outcome recorded |
| Phase 2 | NCT01206582 Comparator | May 2010 → Dec 2014 | diabetes mellitus, gastroparesis | Mayo Clinic | Completed | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2017-07-07 | RECORDATI GROUP | Recordati Rare Diseases Introduces New PANHEMATIN® (Hemin for Injection) Dosage Strength for Treatment of Acute Intermittent Porphyria (AIP), recordati.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Hemin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01855841 ↗ |
| Known as | Panhematin | “Hemin (Panhematin®, Ovation Pharmaceuticals, Deerfield, IL) will be administered through a large-caliber peripheral vein at a dose of 1.25 mL/kg and at a rate of 60 mL/hour.” NCT00882804 ↗ |
| Action | Activate | “Hemin is the most powerful inducer of HO-1.” NCT00882804 ↗ |
| Route | Intravenous | “3 mg/kg i.v. in 25% albumin” NCT00882804 ↗ |